The company s product is bioequivalent and therapeutically equivalent to Atripla Tablets of Gilead Sciences LLC, it added. As per per IQVIA, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumurate tablet (EET) has a market opportunity of USD 7.5 million in the US.
This agreement also gains significance of being the first instance when longer-acting injectable products for HIV prevention are being made available to low and middle-income countries.
i was looking back and forth, watching the soccer game, don t know which channel the ed came on, an advertisement for a new hiv drug, they were advertising to potential users, in the midst of everything they are saying, this drug is not appropriate for people assigned female at birth. i had to stop, put it in neutral and have my brain work, what are they talking about? who can t take this drug? if you think about this, the world in reality is pretty well organized along the lines of biology, including some medicines work for some people and others. now we have to warp language and the jail system around this absurd, no other way to put it, insanity. we are now living in alice in wonderland, absolute insanity. a small byproduct of this, is we prioritize missgendering over prosecuting a child molester.